Based on the previous results, the final combination, i.e. CpG+IL2+HS5 (1:100) + HS 10% + pooled CLL NE, was used as an ex vivo assay in order to test the effect of idelalisib and ibrutinib on 30 cryopreserved samples from CLL patients in need of treatment (Table 3). This evidence concerns the gene IL2 and B-cell chronic lymphocytic leukemia.